
AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing...

Volatility is reshaping the conditions for successful product launches. Market dynamics can shift quickly, assumptions can change, and teams are increasingly expected to make confident decisions in response.

The life sciences industry is changing fast. Advances in AI, increasingly complex science, shifting market dynamics and evolving patient needs are creating new challenges for organizations developing and commercializing treatments....

Inizio has appointed Oisín Ó Gógáin as Chief People Officer.

Remibrutinib reduced relapse rates and improved disease progression rates

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous...

The results for litifilimab support the potential to achieve rapid and durable improvements in skin disease activity

Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?